RxDoctor Payments Data

Beth Bruening, MD

Ophthalmology · Dakota Dunes, SDNPI 1467423517

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $94 of the $114 with a category attached, or 82.9%. 5 manufacturers reported payments, led by AbbVie at 28.8% of the total. Reporting peaked in 2020 at $76 and has fallen 67.5% since, to $25 in 2024. That places this record below the midpoint for ophthalmology clinicians in SD, where the typical reported total is $1,431.

$114in general payments, 2019–2025

Across 6 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$33
  • Regeneron Healthcare Solutions, Inc.$25
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$24
  • Carl Zeiss Meditec AG$19
  • Aerie Pharmaceuticals, Inc.$13

What the payments were for

  • Food & beverage$9483%
  • Gifts$1917%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$114 in reported general payments places this provider in the 20th percentile of 52 ophthalmology providers in South Dakota.

See all ophthalmology providers in South Dakota

Medicare billing

Part B allowed, 2024
$1,019,665
Medicare patients
1,245
Services billed
6,155

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost77$35,523
RestasisCyclosporine18$21,992
Brimonidine Tartrate242$9,415
Prednisolone Acetate205$8,629
Latanoprost643$8,299
RocklatanNetarsudil Mesylat/Latanoprost14$4,934
CombiganBrimonidine Tartrate/Timolol14$4,755
ErythromycinErythromycin Base264$4,133
Brinzolamide19$3,950
Fluorometholone58$3,816
SimbrinzaBrinzolamide/Brimonidine Tart12$2,364
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol19$2,265
Dorzolamide Hcl121$1,782
Timolol Maleate213$1,272
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat101$997

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$33$62,270109 claims
Aerie Pharmaceuticals, Inc.Rocklatan$13$4,93414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 52 ophthalmology providers in South Dakota.

Other ophthalmology in Dakota Dunes

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →